[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.66.254. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 2, 2005

Homocysteine and Fracture Prevention

Author Affiliations
 

Author Affiliations: Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.

JAMA. 2005;293(9):1121-1122. doi:10.1001/jama.293.9.1121

Osteoporotic fractures are a major health problem in Western society and are associated with increased morbidity and mortality and substantial economic costs.1 Because the number of fractures will increase throughout the world as the population ages, prevention of fractures is becoming increasingly important. Recently, studies have identified a new and potentially modifiable risk factor for osteoporotic fracture—a mildly elevated circulating homocysteine level.2,3 These epidemiological studies showed that a relatively high homocysteine level predicts a higher fracture risk but they did not establish a causal relationship. The question remained whether the increase in fracture risk was due to homocysteine itself, or to other covarying factors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×